Information Marketing
Biopartners receives EU marketing authorization for ribavirin 200 mg film-coated tablets for chronic Biopartners … Biopartners GmbH has announced that it has received authorization in the EU market of the European Commission for Biopartners ribavirin 200 mg coated tablets. The product is designed for the treatment of chronic hepatitis C through a combination with peginterferon alfa-2b or interferon alfa-2b. Commenting on the news, Dr Conrad Savoy, CEO of Biopartners said: "We are very …
Dan Kennedy – Information Marketing
